Hikal Ltd reported consolidated revenue of ₹403 crore for the quarter ended June 30, 2026, marking a 6.2% year-on-year growth despite geopolitical and macroeconomic headwinds. The company’s EBITDA expanded significantly by 47.4% to ₹37 crore, driven by an improvement in margins that widened by 260 basis points to 9.2%. However, Hikal recorded a net loss of ₹7 crore for the period, compared to a loss of ₹22 crore in the same quarter last year. The results reflect a transitional phase as the company moves from regulatory-led disruption toward growth, with management citing improving customer demand and execution-led performance.

The pharmaceutical business was the primary growth driver, delivering revenue of ₹233 crore, a 15.2% increase year-on-year. This segment accounted for 58% of total revenue, up from 53% in Q1FY26. The recovery was supported by strengthening demand in regulated markets and improved customer offtake across own products and CDMO operations. Conversely, the crop-protection business saw revenue decline to ₹170 crore from ₹178 crore in the previous year’s corresponding quarter, contributing 42% to the total mix. While own products delivered volume-led growth in domestic markets, CDMO demand remained subdued due to customer inventory adjustments and higher input costs stemming from geopolitical developments.

Financial Performance Overview

Jai Hiremath, Executive Chairman of Hikal Ltd., noted that Q1FY27 represented a slower start as the company transitions from regulatory remediation to growth. He highlighted that significant time and resources were invested in compliance with US FDA recommendations, which temporarily slowed sales in the pharmaceutical business due to planned plant shutdowns. The company is now in the penultimate stage of its remediation plan, with a reinspection expected during the current fiscal year. Hiremath expressed confidence in capitalizing on the CDMO pipeline and specialty APIs in oncology, CNS, gastroenterology, and complex chemistries.

What the Numbers Show

The divergence between revenue growth and net profitability highlights the operational leverage being regained by Hikal. While revenue grew modestly at 6.2%, EBITDA nearly doubled year-on-year, indicating that fixed costs are being absorbed more efficiently as volumes recover. However, the persistence of a net loss, albeit reduced from ₹22 crore to ₹7 crore, suggests that non-operating expenses or one-time charges may still be impacting the bottom line. The shift in revenue mix towards pharmaceuticals (58%) from crop protection (42%) also signals a strategic pivot towards higher-margin regulated markets, supported by an increased DMF filing trajectory of 5–6 filings annually compared to 2–3 historically.

Looking ahead, management expects business momentum to strengthen progressively through FY27. Key initiatives include the commissioning of a new cGMP pilot plant in Pune to enhance pharmaceutical development capabilities and the commercialization of the Personal Care business in July 2026. Additionally, Hikal received a Gold rating from EcoVadis, placing it in the top 5% of companies globally, which reinforces its positioning among global life sciences partners. The company remains focused on expanding CDMO opportunities and achieving operational excellence to drive stepwise recovery in revenues and profitability.

Hikal Limited reported a consolidated net loss of ₹74 million for the quarter ended June 30, 2026, a significant improvement from the ₹224 million loss recorded in the corresponding period of FY25. The company’s total revenue from operations rose 6% year-on-year to ₹4,028 million, driven primarily by growth in its Pharmaceuticals segment. Standalone results mirrored this trend, with a net loss of ₹75 million compared to ₹227 million in Q1FY25. The narrowing loss reflects better operational performance in key segments and favorable exceptional items, including a ₹89 million reduction in employee benefit liabilities due to salary restructuring.

The Board of Directors approved the unaudited financial results at a meeting held on August 06, 2026. The results were reviewed by the Audit Committee on August 05, 2026. S R B C & Co LLP, the statutory auditor, issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window for designated persons will re-open on August 09, 2026, following its closure since July 01, 2026.

Segment Performance

The Pharmaceuticals segment contributed ₹2,333 million to revenue, up from ₹2,026 million in Q1FY25. It returned to profitability with a segment result of ₹75 million, reversing a loss of ₹261 million in the prior year. In contrast, the Crop Protection segment saw revenue decline to ₹1,695 million from ₹1,778 million, reporting a segment loss of ₹60 million compared to a profit of ₹173 million previously. This divergence highlights shifting demand dynamics and potential regulatory headwinds in the agrochemical space.

Key Financial Metrics

Hikal's operational efficiency showed marked improvement, with EBITDA rising to ₹370 million from ₹251 million in Q1FY25, while EBITDA margin expanded to 9.20% from 6.60% over the same period. Total expenses stood at ₹4,234 million, slightly lower than the ₹4,235 million incurred in the standalone books. Finance costs remained stable at ₹149 million. Depreciation and amortization expenses increased to ₹427 million from ₹394 million in Q1FY25. Other income was ₹18 million, down from ₹66 million in the previous quarter but up from ₹10 million in Q1FY25. Tax expense was ₹25 million, comprising deferred tax only, as current tax was nil following a reversal of provisions.

What the Numbers Show

The improvement in net loss is largely attributable to the Pharmaceuticals segment's return to profitability, a ₹89 million exceptional gain from salary restructuring, and a meaningful expansion in EBITDA margins. However, the Crop Protection segment's decline signals ongoing challenges, potentially exacerbated by the USFDA warning letter issued in August 2025 regarding the Jigani facility, which continues to impact Pharma sales. Additionally, the company faces legal uncertainty over alleged environmental non-compliance, with a matter pending before the Supreme Court of India involving a potential compensation of ₹174.5 million, though no further provision has been made as of this quarter.